The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Therapeutic Options for Infections with Enterobacteriaceae Producing Carbapenem-Hydrolyzing Enzymes
Abstract
Enterobacteriaceae that produce serine carbapenemases or metallo-β-lactamases, such as KPC, OXA-48, VIM or NDM, respectively, are spreading mostly as nosocomial pathogens worldwide. Such strains are typically resistant to most if not all available antimicrobials. Specific relevant clinical data are scarce to guide the determination of the most appropriate treatment options. Data on antimicrobial susceptibility, resistance development, synergy, pharmacokinetic and pharmacodynamic parameters of the candidate regimens, as well as the experience from the treatment of infections with nonfermenting Gram-negative pathogens, can aid in this regard. Colistin and tigecycline are most likely to be active in vitro against Enterobacteriaceae producing carbapenem-hydrolyzing β-lactamases, but resistance development is of concern. Individual members of the aminoglycoside class can also be active in vitro, while carbapenems or aztreonam (specifically for metallo-β-lactamase producers) can have low minimum inhibitory concentrations. Current data do not reliably support the use of these agents as monotherapy for systemic infections. Several expanded-spectrum cephalosporins, such as ceftazidime, may be active against OXA-48 type producers. Fosfomycin might be useful as a last-resort option as part of combination regimens. Combination antimicrobial therapy with agents exhibiting synergy might also be of benefit, until novel effective agents could become clinically available.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yigit, H., Queenan, A. M., Anderson, G. J., Domenech-Sanchez, A., Biddle, J. W., Steward, C. D., Alberti, S., Bush, K., & Tenover, F. C. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.4.1151-1161.2001 · Cited by 1,639
Emergence of Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs) in the community
Pitout, J. D. D., Nordmann, P., Laupland, K. B., & Poirel, L. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki166 · Cited by 790
Self-citationLo-Ten-Foe, J. R., de Smet, A. M. G. A., Diederen, B. M. W., Kluytmans, J. A. J. W., & van Keulen, P. H. J. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01406-06 · Cited by 242
Cited by
Liu, Y.-Y., Wang, Y., Walsh, T. R., Yi, L.-X., Zhang, R., Spencer, J., Doi, Y., Tian, G., Dong, B., Huang, X., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00424-7 · Cited by 5,398
Global Spread of Carbapenemase-producing Enterobacteriaceae
Nordmann, P., Naas, T., & Poirel, L. (2011) · Emerging Infectious Diseases · doi:10.3201/eid1710.110655 · Cited by 2,378
Self-citationTzouvelekis, L. S., Markogiannakis, A., Psichogiou, M., Tassios, P. T., & Daikos, G. L. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.05035-11 · Cited by 1,191
OXA-48-like carbapenemases: the phantom menace
Poirel, L., Potron, A., & Nordmann, P. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks121 · Cited by 924
Self-citationCombination Therapy for Treatment of Infections with Gram-Negative Bacteria
Tamma, P. D., Cosgrove, S. E., & Maragakis, L. L. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.05041-11 · Cited by 836
Carbapenem Resistance: A Review
Codjoe, F., & Donkor, E. (2017) · Medical Sciences · doi:10.3390/medsci6010001 · Cited by 746
Rodríguez-Baño, J., Gutiérrez-Gutiérrez, B., Machuca, I., & Pascual, A. (2018) · Clinical Microbiology Reviews · doi:10.1128/cmr.00079-17 · Cited by 704
The emerging NDM carbapenemases
Nordmann, P., Poirel, L., Walsh, T. R., & Livermore, D. M. (2011) · Trends in Microbiology · doi:10.1016/j.tim.2011.09.005 · Cited by 663
Self-citationInfections Caused by Carbapenem-Resistant Enterobacteriaceae: An Update on Therapeutic Options
Sheu, C.-C., Chang, Y.-T., Lin, S.-Y., Chen, Y.-H., & Hsueh, P.-R. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00080 · Cited by 520
Deaths Attributable to Carbapenem-Resistant Enterobacteriaceae Infections
Falagas, M. E., Tansarli, G. S., Karageorgopoulos, D. E., & Vardakas, K. Z. (2014) · Emerging Infectious Diseases · doi:10.3201/eid2007.121004 · Cited by 514
Self-citationWorldwide Dissemination of the NDM-Type Carbapenemases in Gram-Negative Bacteria
Dortet, L., Poirel, L., & Nordmann, P. (2014) · BioMed Research International · doi:10.1155/2014/249856 · Cited by 501
Self-citationEmergence of a novel mobile colistin resistance gene, mcr-8 , in NDM-producing Klebsiella pneumoniae
Wang, X., Wang, Y., Zhou, Y., Li, J., Yin, W., Wang, S., Zhang, S., Shen, J., Shen, Z., & Wang, Y. (2018) · Emerging Microbes & Infections · doi:10.1038/s41426-018-0124-z · Cited by 460
Wang, Y., Zhang, R., Li, J., Wu, Z., Yin, W., Schwarz, S., Tyrrell, J. M., Zheng, Y., Wang, S., Shen, Z., et al. (2017) · Nature Microbiology · doi:10.1038/nmicrobiol.2016.260 · Cited by 434
“Stormy waters ahead”: global emergence of carbapenemases
Patel, G., & Bonomo, R. A. (2013) · Frontiers in Microbiology · doi:10.3389/fmicb.2013.00048 · Cited by 423
Cannatelli, A., D'Andrea, M. M., Giani, T., Di Pilato, V., Arena, F., Ambretti, S., Gaibani, P., & Rossolini, G. M. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01480-13 · Cited by 351
Falagas, M. E., Lourida, P., Poulikakos, P., Rafailidis, P. I., & Tansarli, G. S. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01222-13 · Cited by 351
Self-citationProliferation and significance of clinically relevant β‐lactamases
Bush, K. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12023 · Cited by 337
Tängdén, T., & Giske, C. G. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12342 · Cited by 322
New β-Lactamase Inhibitors: a Therapeutic Renaissance in an MDR World
Drawz, S. M., Papp-Wallace, K. M., & Bonomo, R. A. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00826-13 · Cited by 286
Doumith, M., Godbole, G., Ashton, P., Larkin, L., Dallman, T., Day, M., Day, M., Muller-Pebody, B., Ellington, M. J., de Pinna, E., et al. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw093 · Cited by 263
Alternatives to overcoming bacterial resistances: State-of-the-art
Rios, A. C., Moutinho, C. G., Pinto, F. C., Del Fiol, F. S., Jozala, A., Chaud, M. V., Vila, M. M. D. C., Teixeira, J. A., & Balcão, V. M. (2016) · Microbiological Research · doi:10.1016/j.micres.2016.04.008 · Cited by 263
Metadata
- Authors
- Falagas, M. E., Karageorgopoulos, D. E., & Nordmann, P.
- Venue
- Future Microbiology
- Publisher
- Informa UK Limited
- Published
- 2011-06
- Volume
- 6
- Issue
- 6
- Pages
- 653-666
- ISSN
- 1746-0913 (ISSN-L)
- 1746-0921
- OpenAlex
- W1979421702
- Cited by
- 167
- References
- 3
- FWCI
- 7.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.